Skip to main content

Inventiva enregistre un nouveau brevet pour lanifibranor en Chine étendant la protection de son candidat médicament phare

Written by Customer Service on . Posted in Public Companies.


 Le nouveau brevet délivré par la CNIPA concerne l’utilisation de lanifibranor pour le traitement de plusieurs maladies fibrotiques, dont la NASH, et expire en juin 2035Ce brevet élargit le portefeuille de brevets existant pour lanifibranor dans le deuxième marché pharmaceutique mondial1
Daix (France), le 25 mai 2020 – Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de la stéatohépatite non alcoolique (NASH), des mucopolysaccharidoses (MPS) et d’autres maladies avec un besoin médical non satisfait significatif, annonce aujourd’hui que l’Administration nationale de la propriété intellectuelle de la Chine (China National Intellectual Property Administration – CNIPA) a approuvé un nouveau brevet qui concerne l’utilisation de lanifibranor pour le traitement de plusieurs maladies fibrotiques en Chine jusqu’en juin 2035.Ce nouveau brevet couvre, entre autres, l’utilisation de lanifibranor, le candidat médicament le plus avancé de la Société, pour le traitement de la NASH, la fibrose hépatique, l’insuffisance rénale chronique et le trouble fibrotique pulmonaire. Il vient ainsi étendre la protection de la molécule en Chine, le deuxième marché mondial de l’industrie pharmaceutique[1], et fait suite à un brevet de composé (New Chemical Entity, NCE) délivré précédemment.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.